Effect of Rifampin on Bosutinib When Both Are Given to Healthy People

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Bosutinib

• Registration Number: NCT00725426
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

Study to examine whether rifampin has an effect on the pharmacokinetics of bosutinib.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07
• Study First Submitted: 2008-07-24
• Study First Submitted QC: 2008-07-29
• Study First Posted: 2008-07-30
• Primary Completion: 2008-08
• Study Completion: 2008-08
• Status Verified: 2009-04
• Last Update Submitted: 2009-04-24
• Last Update Posted: 2009-04-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Healthy men age 18-50
• Healthy women of nonchildbearing potential, age 18-50

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Bosutinib	Bosutinib

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics (plasma concentrations)	4 weeks